Emerging health care-associated infections in the geriatric population.

The increasing number of persons >65 years of age form a special population at risk for nosocomial and other health care-associated infections. The vulnerability of this age group is related to impaired host defenses such as diminished cell-mediated immunity. Lifestyle considerations, e.g., travel and living arrangements, and residence in nursing homes, can further complicate the clinical picture. The magnitude and diversity of health care-associated infections in the aging population are generating new arenas for prevention and control efforts

Seed Transmission of the \u3ci\u3eHigh Plains virus\u3c/i\u3e in Sweet Corn

The High Plains virus (HPV), which infects corn and other cereals, was first found in 1993 in the United States. Research was initiated in 1995 to investigate the potential for seed transmission of HPV. Sweet corn seeds of various cultivars harvested in 1994 to 1996 from 13 fields and research plots in southwestern Idaho, Colorado, and Nebraska were seeded in potting mix in the greenhouse. Leaf samples collected at the three- to six-leaf stage from both symptomatic and asymptomatic plants were tested by enzyme-linked immunosorbent assay (ELISA). Of the 46,600 seeds planted, 38,473 seedlings emerged, and three tested positive by ELISA, exhibited mosaic symptoms, and had the presence of HPV confirmed by an additional test. One of the positive plants was used for successful acquisition and transmission of HPV by the wheat curl mite to Westford barley. The other two plants were used to successfully transfer HPV to other corn plants by vascular puncture inoculation of seed. These results indicate that HPV can be seed transmitted at a very low frequency in sweet corn

Evaluation of fungicide and biological treatments for control of fungal storage rots in sugar beet, 2014

Preventing sucrose losses in storage is important to the economic viability of the sugar beet industry. In an effort to establish additional measures for reducing sucrose losses in storage, ten fungicide and/or biological treatments were evaluated on sugar beet roots in a commercial sugar beet storage building for their ability to limit fungal growth on roots harvested 2 Oct. Six of the treatments were applied as a direct spray to roots, but two treatments were applied as a cold fog and two others were applied as a thermal fog. The treated eight-beet root samples were arranged in a randomized complete block design with 6 replications on top of the commercial sugar beet pile inside a storage building. Roots were evaluated for fungal growth, root rot, weight loss, and sucrose reduction. Fungal growth on the root surface ranged from 0 to 58% depending on the rating date and treatment. After 136 days in storage, root rot ranged from 4 to 34%, weight loss ranged from 7.5 to 10.2%, and sucrose reduction ranged from 17 to 33%. The treatments that reduced rot and sucrose reduction the most were Phostrol, Propulse, and Stadium applied as direct sprays and Propulse as a cold fog. Thus, the results indicate that several of the fungicides evaluated have the potential to protect roots from fungal rot in sugar beet storage piles, which could lead to considerable economic benefit for the sugar beet industry

Registration of FC1740 and FC1741 multigerm, rhizomania-resistant sugar beet germplasm with resistance to multiple diseases

FC1740 (Reg No. GP-293, PI 681717) and FC1741 (Reg No. GP-294, PI 681718) sugar beet germplasm (Beta vulgaris L.) were developed by the USDA-ARS at Fort Collins, CO, Salinas, CA, and Kimberly, ID, in cooperation with the Beet Sugar Development Foundation, Denver, CO. These germplasm are diploid, multigerm sugar beet populations in normal cytoplasm, segregating for self-sterility (Sf:SsSs), genetic male sterility (A:aa), and hypocotyl color (R:rr). FC1740 and FC1741 have excellent resistance to rhizomania (Beet necrotic yellow vein virus). FC1740 was selected as homozygous resistant to markers linked to both Rz1 and Rz2 genes for rhizomania resistance. FC1741 was selected as homozygous to the marker linked to the Rz2 gene for resistance. Both germplasm also have resistance to beet curly top (Beet curly top virus) and Fusarium yellows (Fusarium oxysporum Schlechtend.:Fr. f. sp. betae (D. Stewart) W. C. Snyder & H. N. Hans. and other Fusarium spp.), as well as moderate resistance to Aphanomyces root rot (Aphanomyces cochlioides Drechs.). Neither line exhibited resistance to Cercospora leaf spot (Cercospora beticola Sacc.), Rhizoctonia crown and root rot (Rhizoctonia solani Kuhn.) or sugar beet root aphid (Pemphigus spp.). These germplasm provide sources from which to select disease-resistant, multigerm pollinator parents with either or both of the Rz1 and Rz2 sources of rhizomania resistance. Because they are from the same population, they also are useful as controls of known genetic background in comparing entries screened for rhizomania resistance conditioned by Rz1 or Rz2

Integrated Analysis of Clinical and Microbiome Risk Factors Associated with the Development of Oral Candidiasis during Cancer Chemotherapy.

Oral candidiasis is a common side effect of cancer chemotherapy. To better understand predisposing factors, we followed forty-five subjects who received 5-fluorouracil- or doxorubicin-based treatment, during one chemotherapy cycle. Subjects were evaluated at baseline, prior to the first infusion, and at three additional visits within a two-week window. We assessed the demographic, medical and oral health parameters, neutrophil surveillance, and characterized the salivary bacteriome and mycobiome communities through amplicon high throughput sequencing. Twenty percent of all subjects developed oral candidiasis. Using multivariate statistics, we identified smoking, amount of dental plaque, low bacteriome and mycobiome alpha-diversity, and the proportions of specific bacterial and fungal taxa as baseline predictors of oral candidiasis development during the treatment cycle. All subjects who developed oral candidiasis had baseline microbiome communities dominated by Candida and enriched in aciduric bacteria. Longitudinally, oral candidiasis was associated with a decrease in salivary flow prior to lesion development, and occurred simultaneously or before oral mucositis. Candidiasis was also longitudinally associated with a decrease in peripheral neutrophils but increased the neutrophil killing capacity of Candida albicans. Oral candidiasis was not found to be associated with mycobiome structure shifts during the cycle but was the result of an increase in Candida load, with C. albicans and Candida dubliniensis being the most abundant species comprising the salivary mycobiome of the affected subjects. In conclusion, we identified a set of clinical and microbiome baseline factors associated with susceptibility to oral candidiasis, which might be useful tools in identifying at risk individuals, prior to chemotherapy

Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis.

BACKGROUND: Gastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes the primary injury trigger, the interaction of oral microbial commensals with mucosal tissues could modify the response. It is not clear, however, whether chemotherapy and its associated treatments affect oral microbial communities disrupting the homeostatic balance between resident microorganisms and the adjacent mucosa and if such alterations are associated with mucositis. To gain knowledge on the pathophysiology of oral mucositis, 49 subjects receiving 5-fluorouracil (5-FU) or doxorubicin-based chemotherapy were evaluated longitudinally during one cycle, assessing clinical outcomes, bacterial and fungal oral microbiome changes, and epithelial transcriptome responses. As a control for microbiome stability, 30 non-cancer subjects were longitudinally assessed. Through complementary in vitro assays, we also evaluated the antibacterial potential of 5-FU on oral microorganisms and the interaction of commensals with oral epithelial tissues. RESULTS: Oral mucositis severity was associated with 5-FU, increased salivary flow, and higher oral granulocyte counts. The oral bacteriome was disrupted during chemotherapy and while antibiotic and acid inhibitor intake contributed to these changes, bacteriome disruptions were also correlated with antineoplastics and independently and strongly associated with oral mucositis severity. Mucositis-associated bacteriome shifts included depletion of common health-associated commensals from the genera Streptococcus, Actinomyces, Gemella, Granulicatella, and Veillonella and enrichment of Gram-negative bacteria such as Fusobacterium nucleatum and Prevotella oris. Shifts could not be explained by a direct antibacterial effect of 5-FU, but rather resembled the inflammation-associated dysbiotic shifts seen in other oral conditions. Epithelial transcriptional responses during chemotherapy included upregulation of genes involved in innate immunity and apoptosis. Using a multilayer epithelial construct, we show mucositis-associated dysbiotic shifts may contribute to aggravate mucosal damage since the mucositis-depleted Streptococcus salivarius was tolerated as a commensal, while the mucositis-enriched F. nucleatum displayed pro-inflammatory and pro-apoptotic capacity. CONCLUSIONS: Altogether, our work reveals that chemotherapy-induced oral mucositis is associated with bacterial dysbiosis and demonstrates the potential for dysbiotic shifts to aggravate antineoplastic-induced epithelial injury. These findings suggest that control of oral bacterial dysbiosis could represent a novel preventive approach to ameliorate oral mucositis

A shot in the Dark (Ages): a faint galaxy at z=9.76z=9.76 confirmed with JWST

The appearance of galaxies over the first billion years after the Big Bang is believed to be responsible for the last dramatic change in the state of the Universe. Ultraviolet photons from galaxies within this time period - the Epoch of Reionization - ionized intergalactic Hydrogen, rendering the Universe transparent to UV radiation and ending the so-called cosmic Dark Ages, sometime after redshift $z\sim8$. The majority of ionizing photons in the first few hundred Myrs of cosmic history are thought to derive from galaxies significantly fainter than the characteristic luminosity $L^{*}$. These faint galaxies are thought to be surrounded by sufficient neutral gas to prevent the escape of the Lyman-$\alpha$ photons that would allow confirmation with current observatories. Here we demonstrate the power of the recently commissioned James Webb Space Telescope to transform our understanding of the sources of reionization, by reporting the first spectroscopic confirmation of a very low luminosity ($\sim0.05 L^{*}$) galaxy at $z=9.76$, observed 480 Myr after the Big Bang, via the detection of the Lyman-break and redward continuum with the NIRSpec and NIRCam instruments. The galaxy JD1 is gravitationally magnified by a factor of $\mu\sim13$ by the foreground cluster A2744. The power of JWST and lensing allows us to peer deeper than ever before into the cosmic Dark Ages, revealing the compact ($\sim$150 pc) and complex morphology and physical properties of an ultrafaint galaxy ($M_{\rm UV}=-17.45$).Comment: Submitted to Nature. 34 pages, 4 main figures, 1 supplementary figure, 2 supplementary tables. Comments are welcom

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

RATIONALE: Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition. OBJECTIVES: To examine the safety and efficacy of 28 days of once-daily Arikace in cystic fibrosis (CF) patients chronically infected with P aeruginosa. METHODS: 105 subjects were evaluated in double-blind, placebo-controlled studies. Subjects were randomised to once-daily Arikace (70, 140, 280 and 560 mg; n=7, 5, 21 and 36 subjects) or placebo (n=36) for 28 days. Primary outcomes included safety and tolerability. Secondary outcomes included lung function (forced expiratory volume at one second (FEV(1))), P aeruginosa density in sputum, and the Cystic Fibrosis Quality of Life Questionnaire—Revised (CFQ-R). RESULTS: The adverse event profile was similar among Arikace and placebo subjects. The relative change in FEV(1) was higher in the 560 mg dose group at day 28 (p=0.033) and at day 56 (28 days post-treatment, 0.093L±0.203 vs −0.032L±0.119; p=0.003) versus placebo. Sputum P aeruginosa density decreased >1 log in the 560 mg group versus placebo (days 14, 28 and 35; p=0.021). The Respiratory Domain of the CFQ-R increased by the Minimal Clinically Important Difference (MCID) in 67% of Arikace subjects (560 mg) versus 36% of placebo (p=0.006), and correlated with FEV(1) improvements at days 14, 28 and 42 (p<0.05). An open-label extension (560 mg Arikace) for 28 days followed by 56 days off over six cycles confirmed durable improvements in lung function and sputum P aeruginosa density (n=49). CONCLUSIONS: Once-daily Arikace demonstrated acute tolerability, safety, biologic activity and efficacy in patients with CF with P aeruginosa infection

Multi-band analyses of the bright GRB~230812B and the associated SN2023pel

GRB~230812B is a bright and relatively nearby ($z =0.36$) long gamma-ray burst that has generated significant interest in the community and therefore has been subsequently observed over the entire electromagnetic spectrum. We report over 80 observations in X-ray, ultraviolet, optical, infrared, and sub-millimeter bands from the GRANDMA (Global Rapid Advanced Network for Multi-messenger Addicts) network of observatories and from observational partners. Adding complementary data from the literature, we then derive essential physical parameters associated with the ejecta and external properties (i.e. the geometry and environment) and compare with other analyses of this event (e.g. Srinivasaragavan et al. 2023). We spectroscopically confirm the presence of an associated supernova, SN2023pel, and we derive a photospheric expansion velocity of v $\sim$ 17$\times10^3$ km $s^{-1}$. We analyze the photometric data first using empirical fits of the flux and then with full Bayesian Inference. We again strongly establish the presence of a supernova in the data, with an absolute peak r-band magnitude $M_r = - 19.41 \pm 0.10$. We find a flux-stretching factor or relative brightness $k_{\rm SN}=1.04 \pm 0.09$ and a time-stretching factor $s_{\rm SN}=0.68 \pm 0.05$, both compared to SN1998bw. Therefore, GRB 230812B appears to have a clear long GRB-supernova association, as expected in the standard collapsar model. However, as sometimes found in the afterglow modelling of such long GRBs, our best fit model favours a very low density environment ($\log_{10}({n_{\rm ISM}/{\rm cm}^{-3}}) = -2.16^{+1.21}_{-1.30}$). We also find small values for the jet's core angle $\theta_{\rm core}={1.70^{+1.00}_{-0.71}} \ \rm{deg}$ and viewing angle. GRB 230812B/SN2023pel is one of the best characterized afterglows with a distinctive supernova bump